Shares of Second Sight Medical Products Inc. (NASDAQ:EYES) shot up 6% during mid-day trading on Tuesday . The stock traded as high as $4.55 and last traded at $4.40, with a volume of 981,100 shares changing hands. The stock had previously closed at $4.15.

Separately, Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Friday, June 24th.

The stock’s market cap is $151.72 million. The company’s 50-day moving average is $3.79 and its 200 day moving average is $4.57.

Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings results on Thursday, April 28th. The medical device company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the business posted ($0.12) EPS. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.38 million. The firm’s quarterly revenue was down 38.2% compared to the same quarter last year. Analysts predict that Second Sight Medical Products Inc. will post ($0.65) earnings per share for the current fiscal year.

In other news, Chairman Robert J. Greenberg sold 8,571 shares of Second Sight Medical Products stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total value of $35,141.10. Following the sale, the chairman now owns 172,911 shares in the company, valued at $708,935.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman Robert J. Greenberg sold 8,223 shares of Second Sight Medical Products stock in a transaction dated Monday, April 18th. The shares were sold at an average price of $5.27, for a total transaction of $43,335.21. Following the completion of the sale, the chairman now owns 181,134 shares in the company, valued at approximately $954,576.18. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Second Sight Medical Products stock. Zeke Capital Advisors LLC bought a new stake in shares of Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products accounts for 2.5% of Zeke Capital Advisors LLC’s investment portfolio, making the stock its 10th largest position. Zeke Capital Advisors LLC owned 1.38% of Second Sight Medical Products at the end of the most recent quarter.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.